November 24, 2014 3:09 AM ET


Company Overview of Daiichi Sankyo, Inc.

Company Overview

Daiichi Sankyo, Inc. engages in the discovery, development, and commercialization of pharmaceutical products. It offers AZOR for lowering high blood pressure; BENICAR and BENICAR HCT that are prescription medicines used to lower high blood pressure (hypertension); and Effient that is taken with aspirin helps reduce the risk of a future heart-related event, such as a heart attack or blood clot in a stent and in patients who had an acute coronary syndrome event that was treated with angioplasty. The company also provides EVOXAC (cevimeline HCl) for treating symptoms of dry mouth in patients with Sjögren's syndrome; SPRIX that is indicated in adult patients for short-term management of severe p...

Two Hilton Court

Suite 2

Parsippany, NJ 07054

United States

Founded in 1996





Key Executives for Daiichi Sankyo, Inc.

Vice President of Operations
Chief Executive Officer of Daiichi Sankyo Co.
President of Commercial Operations
Age: 51
Executive Vice President and Head of Global Business Development
Compensation as of Fiscal Year 2014.

Daiichi Sankyo, Inc. Key Developments

Daiichi Sankyo, Inc. Appoints Ken Keller as President of Commercial Operations Effective May 1, 2014

Daiichi Sankyo, Inc. announced that Ken Keller will join the company as President of its Commercial operations in the United States starting May 1, 2014. In his role, Mr. Keller will be responsible for leading marketing, sales, medical affairs and supply chain operations for Daiichi Sankyo in the U.S. Ken brings with him more than 25 years of pharmaceutical experience, with career highlights including building a $3 billion business unit as well as leading commercialization for four of the world's top selling biologic medicines. His broad experience and proven success will be a tremendous asset to Daiichi Sankyo. Most recently, Mr. Keller was Executive Vice President and Chief Operating Officer at Spectrum Pharmaceuticals, where he was responsible for global commercial, medical, research and development, and manufacturing. Also responsible for business development at Spectrum, he was integral to the successful acquisition and integration of Talon Therapeutics into the company. Prior to Spectrum, Mr. Keller spent 21 years at Amgen rising through the organization as a respected leader in sales and marketing, general management and joint ventures. He brings with him deep experience in several therapeutic areas aligned with Daiichi Sankyo's focus, including oncology and primary care medicines. His most recent appointments at Amgen were as Vice President and General Manager for two of the company's highly successful business units (bone health and inflammation), as well as Managing Director at Amgen Limited in the United Kingdom and Ireland. With the appointment of Mr. Keller as the head of commercial operations at Daiichi Sankyo, Inc., Dr. Glenn Gormley will assume the role of Executive Chairman and President, Daiichi Sankyo, Inc., and will retain his roles as President, Daiichi Sankyo Pharma Development and as the Global Head of R&D for Daiichi Sankyo Co. Ltd. Greg Barrett, who served as interim president for Commercial operations for the past seven months, will remain Vice President of Marketing and Managed Markets at Daiichi Sankyo, Inc.

Daiichi Sankyo, Inc. Presents at 2013 Therapeutic Area Partnerships Conference, Nov-19-2013 03:10 PM

Daiichi Sankyo, Inc. Presents at 2013 Therapeutic Area Partnerships Conference, Nov-19-2013 03:10 PM. Venue: One Avenue De Lafayette, Boston, MA 02111, United States. Speakers: Weiyong Sun, MD, PhD, Director, External Scientific Affairs.

Daiichi Sankyo, Inc. Announces Two New Executive Appointments

Daiichi Sankyo, Inc. announced that Glenn Gormley, MD, PhD, has been named as corporate President and Chairman of Daiichi Sankyo, Inc. Dr. Gormley will also continue in his existing roles as President, Daiichi Sankyo Pharma Development, Global Head of Research and Development and Senior Executive Officer of Daiichi Sankyo Co. Ltd. In addition, Greg Barrett has been appointed as the new acting head of the Commercial Division of Daiichi Sankyo, Inc. in the U.S. Both appointments are effective as of October 3, 2013. Daiichi Sankyo, Inc.'s former President and CEO, and head of its Commercial Division, John Gargiulo, has left the company effective October 3, 2013. Greg Barrett will hold the new title of Acting President, Daiichi Sankyo Administrative & Commercial Operations. In this role, Mr. Barrett will be responsible for leading the Daiichi Sankyo U.S. Commercial Division including marketing, sales and supply chain operations in the U.S. organization. Mr. Barrett most recently held the position of Vice President, Marketing and Managed Markets, at Daiichi Sankyo, Inc. and has been with the company since the late 1990's.

Similar Private Companies By Industry

Company Name Region
Hypnion, Inc. United States
Gene Pharmaceuticals, LLC United States
Genpharm Limited Partner, Inc. United States
Vitacoat Inc. United States
Supplements Liquidating Trust, LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Daiichi Sankyo, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at